Lack ofp53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions

[1]  J. N. Newton Bishop,et al.  The genetics of melanoma. , 2006, British journal of hospital medicine.

[2]  G. Burg,et al.  Analysis ofras mutations in human melanocytic lesions: activation of theras gene seems to be associated with the nodular type of human malignant melanoma , 2005, Journal of Cancer Research and Clinical Oncology.

[3]  David Lane,et al.  p53 tumour suppressor , 1998, Current Biology.

[4]  Ian Jackson,et al.  Variants of the melanocyte–stimulating hormone receptor gene are associated with red hair and fair skin in humans , 1995, Nature Genetics.

[5]  D. Barker,et al.  Comparison of the responses of human melanocytes with different melanin contents to ultraviolet B irradiation. , 1995, Cancer research.

[6]  R. Eeles,et al.  Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. , 1995, The American journal of pathology.

[7]  T. Leslie Youd,et al.  Structural Aspects , 1995 .

[8]  G. Burg,et al.  Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. , 1995, Journal of cancer research and clinical oncology.

[9]  S. Rauth,et al.  Establishment of a human melanoma cell line lacking p53 expression and spontaneously metastasizing in nude mice. , 1994, Anticancer research.

[10]  R Montesano,et al.  Database of p53 gene somatic mutations in human tumors and cell lines. , 1994, Nucleic acids research.

[11]  X. Montano,et al.  Analysis of p53 in human cutaneous melanoma cell lines. , 1994, Oncogene.

[12]  P. Kleihues,et al.  Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.

[13]  T. Soussi,et al.  Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? , 1994, Mutation research.

[14]  N. Hayward,et al.  Mutation and expression of the p53 gene in human malignant melanoma , 1994, Melanoma research.

[15]  J. Nesland,et al.  TP53 allele loss, mutations and expression in malignant melanoma. , 1994, British Journal of Cancer.

[16]  D. Bishop,et al.  p53 protein detected by immunohistochemical staining is not always mutant. , 1993, Disease markers.

[17]  A. Sober,et al.  Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma , 1993, International journal of cancer.

[18]  R. Tyrrell,et al.  Singlet oxygen: a primary effector in the ultraviolet A/near-visible light induction of the human heme oxygenase gene. , 1993, Cancer research.

[19]  W. Cavenee,et al.  Mutation and expression of the p53 gene in malignant melanoma cell lines , 1993, International journal of cancer.

[20]  Elwood Jm.  Recent developments in melanoma epidemiology, 1993. , 1993 .

[21]  M. Barbareschi,et al.  p53 Protein expression in nevi and melanomas. , 1993, Archives of dermatology.

[22]  B. Epe,et al.  DNA damage induced by photosensitizers in cellular and cell-free systems. , 1993, Mutation research.

[23]  N. S. Mcnutt,et al.  Oncogenes in Melanomas , 1992, The Journal of dermatology.

[24]  M. Kulesz-Martin,et al.  Formation of 8-hydroxydeoxyguanosine within DNA of mouse keratinocytes exposed in culture to UVB and H2O2. , 1992, Carcinogenesis.

[25]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[26]  S. Nishimura,et al.  Photosensitized formation of 8-hydroxydeoxyguanosine in cellular DNA by riboflavin. , 1992, Biochemical and biophysical research communications.

[27]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[28]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[29]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[30]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[31]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[32]  L. Loeb,et al.  8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions. , 1992, The Journal of biological chemistry.

[33]  B. Vogelstein,et al.  Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.

[34]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Harris,et al.  Chemical and physical carcinogenesis: advances and perspectives for the 1990s. , 1991, Cancer research.

[36]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[37]  A. Kimchi,et al.  Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.

[38]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[39]  K. Kinzler,et al.  Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.

[40]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[42]  D. George,et al.  Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.

[43]  U. Schlegel,et al.  Mutational analysis of the human p53 gene in malignant melanoma. , 1991, Pigment cell research.

[44]  B. Epe.  Genotoxicity of singlet oxygen. , 1991, Chemico-biological interactions.

[45]  B. Vogelstein.  A deadly inheritance , 1990, Nature.

[46]  Arnold J. Levine,et al.  The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.

[47]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[48]  J. Yagüe,et al.  AccII polymorphism of the p53 gene. , 1990, Nucleic acids research.

[49]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[50]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[51]  Henry A. Erlich,et al.  PCR Technology: Principles and Applications for DNA Amplification , 1989 .

[52]  W. Blattner,et al.  A cancer family syndrome in twenty-four kindreds. , 1988, Cancer research.

[53]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[54]  T. Soussi,et al.  Cloning and characterization of a cDNA from Xenopus laevis coding for a protein homologous to human and murine p53. , 1987, Oncogene.

[55]  S. Bülow,et al.  [The cancer family syndrome]. , 1981, Ugeskrift for laeger.

[56]  D. Lane,et al.  T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.

[57]  A. Griffiths.  Introduction to Genetic Analysis , 1976 .